This medication is commonly used to help manage clinical conditions where symptomatic support is needed due to the nature of the disease. It is applied across therapeutic areas where short-term symptom management is appropriate to address specific disease characteristics.

The medication is relevant in the treatment of advanced carcinoma of the prostate gland in men, as well as several estrogen-driven gynecological conditions in women, including endometriosis and symptomatic uterine fibroids. Furthermore, its temporary use is relevant for achieving control during in vitro fertilization (IVF) protocols.

Management of Symptoms and Conditions

This therapeutic agent is generally used in situations involving certain distressing symptoms in advanced oncology contexts. The key benefit helps address symptom clusters that may become intense or disruptive associated with the disease, and generally contributes to easing the overall symptom load, which helps patients cope more steadily with symptomatic periods. In situations where patients experience these conditions, the medication may assist with managing the size of growths and is relevant for easing symptoms that interfere with daily functioning, such as chronic pelvic pain and heavy uterine bleeding. Patients often seek this support when symptoms become more disruptive during flare-ups.

“The primary benefit is assisting with maintaining functional stability and contributing to improved day-to-day comfort during symptomatic periods.”

Quick Fact: Relief for Key Symptoms
Oncology: Supports easing the overall symptom load in advanced prostate carcinoma.
Gynecology: Helps manage chronic pain and excessive bleeding in endometriosis and fibroids.
Fertility: Helps manage the conditions where precise control is considered relevant during IVF cycles.

Regulatory References

1. National Cancer Institute (NCI) SEER*Rx database

Eligibility Map: Who can and cannot use Бусерелин-депо — Official Regulatory Information

Eligibility Scope

• Populations for whom use is allowed (as stated in label): Adult men with hormone-dependent advanced prostate carcinoma, and adult women with endometriosis, symptomatic uterine fibroids, or for controlled ovarian stimulation.
• Populations for whom use is contraindicated: Patients with known hypersensitivity to Buserelin or other GnRH agonists. Use is prohibited in women who are pregnant or breastfeeding and in men whose prostate cancer is non-hormone-dependent or who have had an orchiectomy. Contraindication also applies to those with congenital long QT syndrome and undiagnosed abnormal vaginal bleeding.

Age-related eligibility rules

• Adults: Use is established for the primary indications.
• Pediatric Patients (under 18 years): Use for adult indications is not established and no data is available. Use in newborns is avoided if the formulation contains benzyl alcohol.

Condition-specific eligibility rules

• Special Caution/Restricted Use: Requires close supervision for patients with cardiovascular risk factors, diabetes mellitus (due to changes in glucose tolerance), and risk factors for osteoporosis (due to potential for bone mineral density loss).

Eligibility classifications (high-level)

• Eligibility severity classification: Absolute Contraindication, Use with Caution/Close Supervision, Use Not Established.
• Regulatory basis: Prescribing Information (PI) / Summary of Product Characteristics (SmPC) sections on Contraindications and Warnings/Precautions for Special Populations.

Resulting eligibility structure

Official regulatory documentation defines eligibility by establishing non-negotiable contraindications that prohibit use in specific patient groups, such as pregnant women and men with non-hormone-dependent tumors. Eligibility is further limited by cautionary requirements that restrict use in patients with pre-existing conditions like cardiovascular disease, diabetes, or risk factors for bone loss, necessitating close monitoring as explicitly detailed in the labeled precautions.

The officially documented interaction profile for Buserelin depot is defined by functional and pharmacodynamic interactions, as detailed in regulatory prescribing information. The profile does not contain statements regarding metabolic interactions involving CYP450 enzymes or drug transporters.

Documented Pharmacodynamic Interactions

The co-administration of Buserelin with other sex hormones (Estrogens or Androgens) is considered a contra-therapeutic combination, as these substances may oppose the drug’s primary purpose of sex hormone suppression.

Due to Buserelin’s documented potential to induce a mild, transient prolongation of the QT interval, co-administration with other medicinal products known to prolong the QT interval (such as certain Class IA or Class III antiarrhythmics) requires careful assessment because of the risk of additive cardiac effects, as noted in government labels.

Additionally, the efficacy of antidiabetic medicinal products (e.g., sulfonylureas) may be reduced when co-administered, a risk associated with Buserelin’s documented influence on glucose tolerance.

Other Interaction Considerations

Official regulatory documents do not specify any mandatory timing-based separation rules for co-administration. Furthermore, the prescribing information does not contain documented interactions with food, alcohol, herbal products, or supplements for the injectable depot formulation.

The mechanism of Buserelin-depot is defined by its strategic, two-part action on the central hormonal command center, leading to a substantial reduction in sex hormone production.

Central Pituitary Receptor Down-Regulation

The active substance, Buserelin, acts as a superagonist on the Gonadotropin-Releasing Hormone Receptors (GnRHR) located on the pituitary gland. The continuous, non-pulsatile exposure delivered by the depot formulation forces the down-regulation and desensitization of these receptors. This mechanism shuts down the pituitary's ability to respond to hormonal signals, which is an essential step in the cascade that leads to suppression.

Biphasic HPG Axis Suppression

The mechanism begins with a transient surge of LH and FSH (the "flare effect") due to the initial forced stimulation. Following this, the sustained GnRHR down-regulation blocks the release of LH and FSH (Hypogonadotropism), which removes the crucial signal required by the gonads. This systemic shut-down of the entire Hypothalamic-Pituitary-Gonadal (HPG) Axis leads directly to the physiological consequence: a reduction in circulating Testosterone and Estradiol levels to near-castration concentrations (Chemical Hypogonadism).

Constraints of the Endocrine Mechanism

While Buserelin effectively suppresses sex hormone production governed by the HPG axis (gonadal sources), its action is constrained. A small, residual portion of sex hormones produced by the adrenal glands operates independently of the GnRH receptor mechanism and therefore remains unaffected, establishing a physiological floor for the achievable level of sex hormone reduction.

How Бусерелин-депо is Used: Official Administration Guidelines

Бусерелин-депо (Buserelin depot/implant) is administered exclusively as a depot preparation designed for long-term therapeutic effect. Its usage is directed by standard clinical instructions to ensure the consistent, sustained suppression of sex hormone production.

---

Administration Protocol

Feature	Guideline Based on Official Labeling
Route of Administration	Subcutaneous injection (SC), typically into the abdominal wall. The procedure must be performed by a healthcare professional.
Dosing Schedules	6.3 mg implant administered every two months, or 9.45 mg implant administered every three months for advanced prostatic carcinoma.
Initial Treatment Phase	An anti-androgen is required to be started about 5 days before the first depot injection and continued for the first 3 to 4 weeks to manage initial hormonal fluctuation.

---

Frequency and Procedural Conditions

This medication is intended for long-term therapy, and injections must occur at approximately equal intervals. A considerable extension of the two- or three-month dosing interval may lead to the recovery of sex hormone secretion, requiring adherence to the defined schedule.

For administration, the depot device should be allowed to reach room temperature prior to use, and proper device handling (such as keeping the syringe horizontal) is often specified in the preparation instructions.

Population Restrictions

Official labeling specifies that the safety and efficacy of Бусерелин-депо have not been established in the pediatric population, and its use is restricted to adults. No explicit dose adjustments are mandated for older adults or for patients with renal or hepatic impairment.

Research Evidence / Overview of Studies for Бусерелин-депо

Evidence for Use in Prostate Carcinoma

The research base for the use of this medicine in adult men with advanced carcinoma of the prostate gland includes Randomized Controlled Trials (RCTs) and long-term trials. These research scenarios were used to monitor specific physiological goals related to hormonal suppression, primarily focusing on achieving and maintaining the suppression of serum testosterone to very low levels (castrate levels). Research monitored long-term endpoints, including progression-free survival and overall survival.

Evidence for this indication is generally labeled as High by scientific reviews, reflecting the volume and alignment of data related to the key hormonal outcome. Studies report how survival outcomes evolved in the observed populations, and research continues to explore outcomes against all current therapeutic options.

---

Evidence for Use in Gynecological Conditions (Endometriosis and Uterine Fibroids)

For conditions such as endometriosis and symptomatic uterine fibroids, the research has focused on adult women of reproductive age in clinical trials and systematic reviews. The studies explored how symptoms change over time, tracking outcomes related to physical discomfort (e.g., chronic pelvic pain, heavy uterine bleeding) and objective outcomes like the reduction in lesion size or fibroid volume.

The findings describe patterns observed during the short, pre-defined treatment period (typically limited to 6 months). However, for some symptom-related outcomes in endometriosis, systematic reviews have indicated that evidence quality varies across studies, and certainty remains low to moderate due to study design factors.

---

What is Still Uncertain in the Research Landscape

Research contributes to the broader evidence landscape, but several aspects remain uncertain or limited. The data for long-term outcomes following the short-term use in endometriosis and uterine fibroids are limited, particularly concerning the durability of symptom response and the risk of symptom return. Findings for pain relief in endometriosis were mixed in some reviews, and evidence quality varies across studies, with a need for more consistent patient-reported outcomes.

Furthermore, comparative evidence against all current treatment protocols is still emerging, as many pivotal studies utilized older comparators. Researchers note that the study results reflect the specific conditions and protocols under which they were conducted and research provides context but not individual predictions regarding long-term response.

Key Studies & References

1. A pharmacological evaluation of a new 3-month depot preparation of buserelin for prostatic cancer
2. A narrative review of using GnRH analogues to reduce endometriosis recurrence after surgery: a double-edged sword - Gynecology and Pelvic Medicine

Common questions about Бусерелин-депо (FAQ)

---

Q: Is Бусерелин-депо a hormonal drug or not?

A: According to official product information, the active substance is a synthetic peptide analog of the natural hormone GnRH, which acts as a GnRH superagonist. While it is not a traditional sex hormone, its primary function is to profoundly affect the production of sex hormones in the body, placing it in the category of hormonal regulators.

Q: What is the typical duration of treatment with Бусерелин-депо?

A: The required duration of therapy varies depending on the medical condition being treated. For gynecological conditions, regulatory documents typically indicate that treatment is limited to about six months. For advanced prostatic carcinoma, the medication is generally intended for long-term therapy.

Q: What kind of sensations can be expected after the first injection of Бусерелин-депо?

A: The medication's initial action causes a temporary surge in hormones known as the 'flare effect.' Official documents note that in men, this can be associated with a temporary worsening of symptoms. Regulatory documents recommend that patients inform their healthcare provider about any symptoms experienced during treatment.

Q: What is the official guidance regarding driving or operating machinery while using Бусерелин-депо?

A: Official information advises caution because the medication may cause side effects that could affect alertness. Documented adverse reactions include dizziness, sleep disturbances, or visual impairment. If these effects occur, the ability to safely drive or operate machinery may be impaired.

Q: How does Бусерелин-депо affect bone tissue with long-term use?

A: Official warnings state that treatment with GnRH agonists can cause a decrease in bone mineral density. Official warnings note that the decrease in bone mineral density is a consideration for long-term exposure, with the magnitude of bone loss related to the duration of therapy.

Q: What is the 'flare effect' when starting Бусерелин-депо therapy?

A: The 'flare effect' is the transient surge in Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) that occurs when the treatment is first initiated. This surge is caused by the initial strong stimulation of the pituitary gland, leading to a temporary increase in sex hormone levels before the suppressive effect begins.

Q: Why might symptoms temporarily worsen after starting Бусерелин-депо treatment?

A: The temporary worsening of symptoms, often called a 'disease flare,' is related to the drug's mechanism of action. It is caused by the initial, transient surge of sex hormones that occurs before the medication's intended suppressive effect takes hold.

Q: Does Бусерелин-депо interact with contraceptives?

A: Official prescribing information indicates that co-administration with sex hormones, such as estrogens or androgens, is considered a contra-therapeutic combination. This is because these substances may counteract the medication's primary goal of suppressing sex hormone production.

Q: What is the main effect expected from Бусерелин-депо?

A: The therapeutic goal of the medication is to achieve and maintain a substantial suppression of sex hormone production. By suppressing the levels of estradiol and testosterone, the drug helps manage hormone-dependent conditions.

Q: How many days or weeks does it take for Бусерелин-депо to start working?

A: The official pharmacological data indicates that hormone levels begin to fall within two to four weeks after treatment initiation. The maximum, sustained level of hormone suppression is typically achieved by about eight weeks.

Q: Is there a link between Бусерелин-депо and weight gain?

A: Official adverse reaction lists state that both an increase or a decrease in weight are documented side effects of the medication. This falls under the classification of frequent metabolism and nutrition disorders.

Q: Can Бусерелин-депо affect mood or emotional state?

A: Yes, official safety information lists several related effects. Documented side effects include mood changes, depression (or the worsening of existing depression), nervousness, and emotional instability.

Q: Can Бусерелин-депо affect libido?

A: Yes, according to official adverse reaction classifications, decreased libido, or sex drive, is a documented and very common side effect of the medication.

Q: How quickly does the menstrual cycle recover after stopping Бусерелин-депо?

A: The suppression of the hormonal axis is generally considered reversible, with the return of normal menstrual cycles typically occurring a few months after the treatment is discontinued.

Q: How does Бусерелин-депо affect the skin and hair?

A: Documented skin-related effects, categorized as hypersensitivity reactions, include skin rashes (such as urticaria), itching, and reddening of the skin. Specific effects on hair are not explicitly detailed in the adverse reaction profile.

Q: How is the effectiveness of Бусерелин-депо typically monitored?

A: The effectiveness of the medication is confirmed pharmacologically by achieving a sustained suppression of sex hormones. This means the blood levels of serum estradiol and testosterone should be reduced to near castrate concentrations.

Q: In what cases is Бусерелин-депо discontinued?

A: The drug is contraindicated in certain patient groups and must be discontinued if an absolute contraindication is found. This includes a known hypersensitivity to Buserelin or other GnRH agonists.

Q: What is known about the long-term effects of Бусерелин-депо?

A: For long-term use, regulatory documents specifically note the risk of decreased bone mineral density and subsequent osteoporosis. Additionally, there are warnings regarding the potential for cardiovascular events and the worsening of glucose tolerance with prolonged GnRH agonist treatment.

Q: Why is it important not to miss Бусерелин-депо injections?

A: Official dosing instructions emphasize the importance of strict adherence to the defined schedule. Extending the dosing interval significantly may lead to the recovery of sex hormone secretion, which could reduce the intended therapeutic effect of the treatment.

Q: What is the guidance regarding planning a pregnancy after completing the Бусерелин-депо course?

A: The drug is contraindicated during pregnancy due to the risk of fetal harm. Official information notes that due to the risk of fetal harm, non-hormonal contraception should be used until the return of menstruation following treatment discontinuation.

Q: Why is Бусерелин-депо sometimes prescribed to women before surgery?

A: The medication is indicated for conditions like symptomatic uterine fibroids. In these cases, it may be used for a defined period to reduce the size of the fibroid lesion prior to a planned surgical procedure.

Q: How often do allergic reactions to Бусерелин-депо occur?

A: Allergic reactions like skin rashes, itching, and reddening of the skin are documented side effects. Rare but very serious reactions, including anaphylactic or anaphylactoid shock, are also specified in the safety profile.

Q: Does Бусерелин-депо affect blood pressure?

A: Official adverse reaction data includes reports of a deterioration of blood pressure levels in very rare cases, particularly in patients who have pre-existing hypertension.

Q: What does official documentation say about managing common side effects like hot flushes from Бусерелин-депо?

A: While hot flushes and discomfort are common side effects, regulatory documents state that these adverse reactions may necessitate symptomatic treatment. Specific patient self-management advice is not detailed in the official safety profile.

Q: What type of patient monitoring is noted in official documentation for use with Бусерелин-депо?

A: Monitoring is noted in official documentation for patients with pre-existing health conditions. For example, patients with diabetes must be monitored for potential glucose intolerance, and those at risk for osteoporosis require monitoring of factors related to bone mineral density.

Q: What are the specific requirements for preparing the Бусерелин-депо product before injection?

A: Preparation instructions focus on the product itself. Regulatory documents specify that the depot preparation must be handled according to specific instructions, such as allowing the device to reach room temperature prior to use.

Official Storage and Disposal Instructions

The storage of Buserelin depot must strictly follow regulatory instructions to ensure product stability. The medication is required to be stored at a controlled room temperature, though some specific products may require storage in a refrigerator (2, C to 8, C) before the day of administration. The product must be kept in its original container, protected from heat and light, and must not be frozen.

All Buserelin preparations must be stored out of the sight and reach of children and pets.

For disposal, unused or expired medicine must be thrown away according to local rules or returned to a pharmacy. The product must not be flushed down a toilet or poured down a drain. Used needles and syringes must be placed immediately into an approved sharp disposal box.